Search results
...Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-...
Digital Journal· 3 days agoThis current study...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 6 hours agoUpdates from BMY: Bristol Myers BMY announced that the FDA had granted accelerated approval to the...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 1 day agoPreliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma ...
US FDA approves expanded use of Bristol’s cancer cell therapy
WHTC 1450 Holland· 1 day ago(Reuters) -The U.S. health regulator said on Wednesday it has approved the expanded use of Bristol...
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
ThePress.net· 2 days ago"We continue to build momentum in the clinical development of our lead product candidate, KYV-101, as we seek to bring autoimmune CAR T-cell therapies to ...
Moleculin begins NIH-funded Phase II glioblastoma treatment trial
Clinical Trials Arena via Yahoo Finance· 12 hours agoThe trial is being conducted under Northwestern University's Investigative New Drug application,...
Fighting lymphoma: Treatment options include alternatives to chemotherapy, expert explains
Medical Xpress· 1 day agoChemotherapy is usually the first treatment doctors try to treat lymphoma, including the two most...
Lymphoma: Know Your Treatment Options
WFMZ Eastern Pennsylvania and Western New Jersey· 12 hours agoFor anyone newly diagnosed with blood cancers known as lymphomas, their first question might be: What treatments can help? Of course, there have been big...
US FDA approves expanded use of Bristol Myers' cancer cell therapy (May 15)
AOL· 1 day agoThe Food and Drug Administration's decision marks the fourth approval for Breyanzi, which can now be used to treat follicular lymphoma patients who have received two or more prior lines of & ...
Precigen Reports First Quarter 2024 Financial Results and Business Updates
WRBL Columbus· 2 days ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation ...
